## CytoSorb®



## Best practice flowchart **Aortic surgery**



Therapy goal

Reduction of complications through:

- · Stabilization of hemodynamics
- · Reduction of bleeding risks
- Support lung function



**Patient selection** 

CytoSorb® Therapy may be considered during cardiac surgery in complex aortic surgery.

Additional criteria for intraoperative use of CytoSorb® intraoperatively in aortic surgery patients may be the following:

- High preoperative lactate
- · Planned deep hypothermic circulatory arrest
- Planned cerebral perfusion
- Hemodynamic instability requiring high vasopressor support



**Timing** 


Start therapy with the start of cardiopulmonary bypass (CPB). CytoSorb® is easily integrated into the CPB circuit (post-pump to venous reservoir)



**Dosing** 

Consider postoperative continuation of CytoSorb® Therapy (with a new adsorber integrated into an extracorporeal circuit) in aortic surgery patients when the following signs are observed intraoperatively:

- Development of intraoperative oliguric / anuric renal failure
- Increased norepinephrine / vasopressin requirements
- Unexpected intraoperative findings e.g. significant visceral ischemia



\* Integration into CRRT, ECMO, Hemoperfusion



Learn more in detail cyto.zone/setup

\*\* For details please see CytoSorb® flowchart septic/vasoplegic shock



cyto.zone/flow-sep/eng



## CytoSorbents Europe GmbH

Müggelseedamm 131 12587 Berlin | Germany T +49 30 65 49 91 45 F +49 30 65 49 91 46 support@cytosorbents.com **STOP** 

CytoSorb®